Literature DB >> 20520636

Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma.

S Kumar1, L Zhang, A Dispenzieri, S Van Wier, J A Katzmann, M Snyder, E Blood, R DeGoey, K Henderson, R A Kyle, A R Bradwell, P R Greipp, S V Rajkumar, R Fonseca.   

Abstract

Elevated immunoglobulin free light chain (FLC) level and abnormal FLC ratio are commonly seen in multiple myeloma (MM) and have prognostic implications. We hypothesized that presence of immunoglobin heavy chain (IgH) translocations leads to unbalanced production of light chains and more extreme abnormalities of FLC, and may explain the prognostic value of FLC. We studied 314 patients with newly diagnosed MM enrolled in a phase III trial, in whom results of fluorescence in situ hybridization testing and data on serum FLC levels were available. Cytogenetic analyses and FLC estimates were performed on stored samples and results were correlated with clinical data. The median ratio (FLC ratio) and the absolute difference (FLC diff) between the involved and uninvolved FLC were higher among those with IgH translocations, especially t(14;16). In multivariate analysis, the prognostic value of FLC estimates on progression-free and overall survival were independent of high-risk IgH translocations t(4;14) and t(14;16). A combination of the risk factors; either abnormal FLC estimate and/or the presence of high-risk IgH translocation, achieved better prognostic stratification. We conclude that patients with IgH translocations have higher FLC levels and abnormal ratios, but the prognostic effect of FLC is only partially explained by translocation status. A system including both these risk factors allows better prediction of outcome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20520636      PMCID: PMC3558529          DOI: 10.1038/leu.2010.128

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  43 in total

1.  A mouse myeloma variant with a defect in light chain synthesis.

Authors:  S L Morrison; M D Scharff
Journal:  Eur J Immunol       Date:  1979-06       Impact factor: 5.532

2.  T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burden.

Authors:  E Halapi; A Werner; J Wahlström; A Osterborg; M Jeddi-Tehrani; Q Yi; C H Janson; H Wigzell; J Grunewald; H Mellstedt
Journal:  Eur J Immunol       Date:  1997-09       Impact factor: 5.532

Review 3.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2004-10-28       Impact factor: 91.245

4.  Ig light chains are secreted predominantly as monomers.

Authors:  J L Dul; S Aviel; J Melnick; Y Argon
Journal:  J Immunol       Date:  1996-10-01       Impact factor: 5.422

5.  Coordination of immunoglobulin chain folding and immunoglobulin chain assembly is essential for the formation of functional IgG.

Authors:  C R Kaloff; I G Haas
Journal:  Immunity       Date:  1995-06       Impact factor: 31.745

6.  Immunoglobulin heavy chain toxicity in plasma cells is neutralized by fusion to pre-B cells.

Authors:  I G Haas; M R Wabl
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

7.  A possible mechanism of inability of immunoglobulin heavy-chain production in Bence-Jones type myeloma cells.

Authors:  A Sakai; M M Kawano; O Tanabe; A Kuramoto
Journal:  Int J Hematol       Date:  1993-12       Impact factor: 2.490

8.  Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor. II. Characterization of anti-idiotypic CTL lines and clones.

Authors:  D Chakrabarti; S K Ghosh
Journal:  Cell Immunol       Date:  1992-10-15       Impact factor: 4.868

9.  Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation.

Authors:  M H Bakkus; C Heirman; I Van Riet; B Van Camp; K Thielemans
Journal:  Blood       Date:  1992-11-01       Impact factor: 22.113

10.  Exon skipping without splice site mutation accounting for abnormal immunoglobulin chains in nonsecretory human myeloma.

Authors:  M Cogné; P Guglielmi
Journal:  Eur J Immunol       Date:  1993-06       Impact factor: 5.532

View more
  12 in total

1.  Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.

Authors:  Shaji Kumar; Angela Dispenzieri; Jerry A Katzmann; Dirk R Larson; Colin L Colby; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Nelson Leung; Steve R Zeldenrust; Marina Ramirez-Alvarado; Raynell J Clark; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz
Journal:  Blood       Date:  2010-08-26       Impact factor: 22.113

Review 2.  Risk Stratification in Multiple Myeloma in Indian Settings.

Authors:  Rajan Kapoor; Rajiv Kumar; A P Dubey
Journal:  Indian J Hematol Blood Transfus       Date:  2019-12-14       Impact factor: 0.900

3.  Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts.

Authors:  Iman Meziane; Stefanie Huhn; Miguel Inacio da Silva Filho; Niels Weinhold; Chiara Campo; Jolanta Nickel; Per Hoffmann; Markus M Nöthen; Karl-Heinz Jöckel; Stefano Landi; Jonathan S Mitchell; David Johnson; Anna Jauch; Gareth J Morgan; Richard Houlston; Hartmut Goldschmidt; Paolo Milani; Giampaolo Merlini; Dorota Rowcieno; Philip Hawkins; Ute Hegenbart; Giovanni Palladini; Ashutosh Wechalekar; Asta Försti; Stefan O Schönland; Kari Hemminki
Journal:  Haematologica       Date:  2017-07-04       Impact factor: 9.941

4.  Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels.

Authors:  Pankaj Yadav; Maximilian Merz; Elias K Mai; Asta Försti; Anna Jauch; Hartmut Goldschmidt; Kari Hemminki
Journal:  Haematologica       Date:  2018-02-01       Impact factor: 9.941

5.  Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

Authors:  Nikhil C Munshi; Kenneth C Anderson; P Leif Bergsagel; John Shaughnessy; Antonio Palumbo; Brian Durie; Rafael Fonseca; A Keith Stewart; Jean-Luc Harousseau; Meletios Dimopoulos; Sundar Jagannath; Roman Hajek; Orhan Sezer; Robert Kyle; Pieter Sonneveld; Michele Cavo; S Vincent Rajkumar; Jesus San Miguel; John Crowley; Hervé Avet-Loiseau
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

6.  Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.

Authors:  S V Rajkumar; V Gupta; R Fonseca; A Dispenzieri; W I Gonsalves; D Larson; R P Ketterling; J A Lust; R A Kyle; S K Kumar
Journal:  Leukemia       Date:  2013-03-21       Impact factor: 11.528

7.  Impact of genetic abnormalities on the prognoses and clinical parameters of patients with multiple myeloma.

Authors:  Dong Wook Jekarl; Chang-Ki Min; Ahlm Kwon; Hyunjung Kim; Hyojin Chae; Myungshin Kim; Jihyang Lim; Yonggoo Kim; Kyungja Han
Journal:  Ann Lab Med       Date:  2013-06-24       Impact factor: 3.464

Review 8.  Interpretation of cytogenetic results in multiple myeloma for clinical practice.

Authors:  A M Rajan; S V Rajkumar
Journal:  Blood Cancer J       Date:  2015-10-30       Impact factor: 11.037

9.  Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012.

Authors:  Vânia Tietsche de Moraes Hungria; Edvan de Queiroz Crusoe; Adriana Alvarez Quero; Manuella Sampaio; Angelo Maiolino; Wanderley Marques Bernardo
Journal:  Rev Bras Hematol Hemoter       Date:  2013

Review 10.  Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications.

Authors:  Linchun Xu; Yongzhong Su
Journal:  Exp Hematol Oncol       Date:  2021-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.